1. Home
  2. GPATU vs NNVC Comparison

GPATU vs NNVC Comparison

Compare GPATU & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPATU
  • NNVC
  • Stock Information
  • Founded
  • GPATU N/A
  • NNVC 2005
  • Country
  • GPATU
  • NNVC United States
  • Employees
  • GPATU N/A
  • NNVC N/A
  • Industry
  • GPATU
  • NNVC Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPATU
  • NNVC Health Care
  • Exchange
  • GPATU NYSE
  • NNVC Nasdaq
  • Market Cap
  • GPATU N/A
  • NNVC 22.5M
  • IPO Year
  • GPATU N/A
  • NNVC N/A
  • Fundamental
  • Price
  • GPATU $10.66
  • NNVC $1.59
  • Analyst Decision
  • GPATU
  • NNVC
  • Analyst Count
  • GPATU 0
  • NNVC 0
  • Target Price
  • GPATU N/A
  • NNVC N/A
  • AVG Volume (30 Days)
  • GPATU N/A
  • NNVC 239.9K
  • Earning Date
  • GPATU N/A
  • NNVC 05-15-2025
  • Dividend Yield
  • GPATU N/A
  • NNVC N/A
  • EPS Growth
  • GPATU N/A
  • NNVC N/A
  • EPS
  • GPATU N/A
  • NNVC N/A
  • Revenue
  • GPATU N/A
  • NNVC N/A
  • Revenue This Year
  • GPATU N/A
  • NNVC N/A
  • Revenue Next Year
  • GPATU N/A
  • NNVC N/A
  • P/E Ratio
  • GPATU N/A
  • NNVC N/A
  • Revenue Growth
  • GPATU N/A
  • NNVC N/A
  • 52 Week Low
  • GPATU N/A
  • NNVC $0.94
  • 52 Week High
  • GPATU N/A
  • NNVC $2.55
  • Technical
  • Relative Strength Index (RSI)
  • GPATU N/A
  • NNVC 51.78
  • Support Level
  • GPATU N/A
  • NNVC $1.34
  • Resistance Level
  • GPATU N/A
  • NNVC $1.44
  • Average True Range (ATR)
  • GPATU 0.00
  • NNVC 0.08
  • MACD
  • GPATU 0.00
  • NNVC 0.00
  • Stochastic Oscillator
  • GPATU 0.00
  • NNVC 90.10

About GPATU GP-ACT III ACQUISITION CORP

GP-Act III Acquisition Corp is a blank check company.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: